Lymphoma
Conditions
Keywords
recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3 follicular lymphoma, contiguous stage II grade 1 follicular lymphoma, contiguous stage II grade 2 follicular lymphoma, contiguous stage II grade 3 follicular lymphoma, noncontiguous stage II grade 1 follicular lymphoma, noncontiguous stage II grade 2 follicular lymphoma, noncontiguous stage II grade 3 follicular lymphoma, stage III grade 1 follicular lymphoma, stage III grade 2 follicular lymphoma, stage III grade 3 follicular lymphoma, stage IV grade 1 follicular lymphoma, stage IV grade 2 follicular lymphoma, stage IV grade 3 follicular lymphoma
Brief summary
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Radiolabeled monoclonal antibodies, such as yttrium Y 90 ibritumomab tiuxetan, can find cancer cells and carry cancer-killing substances to them without harming normal cells. Giving rituximab together with combination chemotherapy and yttrium Y 90 ibritumomab tiuxetan may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving rituximab together with combination chemotherapy and yttrium Y 90 ibritumomab tiuxetan works in treating patients with relapsed follicular non-Hodgkin lymphoma.
Detailed description
OBJECTIVES: Primary * To evaluate the response rates in patients with relapsed follicular non-Hodgkin lymphoma treated with short-duration rituximab and combination chemotherapy (R-chemo) followed by rituximab and yttrium Y 90 ibritumomab tiuxetan. Secondary * To evaluate the duration of response in patients treated with this regimen. * To evaluate the quality of response in order to determine the conversion rate from partial response to complete response in patients treated with this regimen. * To evaluate the toxicity of yttrium Y 90 ibritumomab tiuxetan when administered after 3 courses of R-chemo. OUTLINE: This is a multicenter study. * Chemoimmunotherapy (R-CHOP or R-CVP): Patients receive R-CHOP comprising rituximab IV, cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine IV on day 1 and oral prednisolone on days 1-5. Alternatively, patients who have already been exposed to prior tolerance doses of anthracyclines receive R-CVP comprising rituximab IV, cyclophosphamide IV, and vincristine IV on day 1 and oral prednisolone on days 1-5. Treatment repeats every 3 weeks for up to 3 courses. Patients with objective evidence of response on CT scan or those with \< 25% bone marrow involvement and no signs of bone marrow hypocellularity (\< 15%) on bone marrow biopsy proceed to radioimmunotherapy. * Radioimmunotherapy: Four to 6 weeks after completion of R-CHOP or R-CVP, patients receive rituximab IV followed no more than 4 hours later by yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes. After completion of study therapy, patients are followed periodically for up to 5 years.
Interventions
BIOLOGICALrituximab
DRUGcyclophosphamide
DRUGdoxorubicin hydrochloride
DRUGprednisolone
DRUGvincristine sulfate
RADIATIONyttrium Y 90 ibritumomab tiuxetan
Sponsors
University of Southampton
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 120 Years
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Histologically confirmed grade 1, 2, or 3 follicular non-Hodgkin lymphoma * Stage II, III, or IV disease (according to the Ann Arbor staging system) * CD20-positive disease * Initial disease bulk ≤ 10 cm * In first or second relapse after prior treatment with a rituximab-containing chemotherapy regimen (R-chemo) or chemotherapy alone * Relapse must have occurred ≥ 6 months after completion of R-chemo * Relapse that occurred \< 6 months after completion of chemotherapy alone allowed * Has at least one of the following symptoms requiring initiation of treatment: * Nodal mass \> 5 cm in its greater diameter * B symptoms * Elevated serum lactate dehydrogenase (LDH) or β2-microglobulin * Involvement of ≥ 3 nodal sites (each with a diameter \> 3 cm) * Symptomatic splenic enlargement * Compressive syndrome * No primary refractory disease * No large pleural or peritoneal effusions * No CNS disease PATIENT CHARACTERISTICS: * ECOG performance status 0-2 * Life expectancy ≥ 6 months * Absolute granulocyte count ≥ 1,500/mm³ * Platelet count ≥ 1,000/mm³ * Serum creatinine \< 1.5 times upper limit of normal (ULN) * Total bilirubin \< 1.5 times ULN * AST \< 5 times ULN * No active obstructive hydronephrosis * No evidence of active infection requiring IV antibiotics * No advanced heart disease or other serious illness that would preclude study evaluation * No known HIV infection * No human anti-mouse antibody (HAMA) reactivity * No known hypersensitivity to murine antibodies or proteins * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for 12 months after completion of study treatment * No other prior malignancy, except for adequately treated skin cancer, cervical cancer in situ, or other cancer for which the patient has been disease-free for 5 years PRIOR CONCURRENT THERAPY: * See Disease Characteristics * At least 4 weeks since prior investigational drugs and recovered * No prior radioimmunotherapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall response rate, including combined complete response and partial response | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to disease progression | — |
| Time to next treatment | — |
| Response duration in patients with responding disease | — |
| Safety | — |
Countries
United Kingdom
Outcome results
None listed